KEY FUNDAMENTAL POINTS
- Taiyo Holdings is a Japan-based global chemical manufacturer known for its leadership in solder resist (SR) materials used in printed circuit boards (PCBs). The company holds >53% of the entire global market for liquid-type solder resist. It is also nearly monopolistic in dry film solder resist market with at least 84% global share.
- The company operates under three main business segments: Electronics (68%); Medical and Pharma (28%) and ICT/Sustainability (4%). 64% of its total revenue comes from international markets.
- Taiyo’s electronic segment is expected to benefit from surging global demand for advanced PCBs in AI, EVs, HPC, and IoT applications, alongside its ongoing expansion into non-SR electronic materials.
- The company is expanding beyond the cyclical electronics business. It is capitalizing on high demand for long-listed drugs in Japan, driven by healthcare cost pressures and supply shortages.
- It aims to become a key player in the growing Contract Development and Manufacturing Organization (CDMO) sector, providing end-to-end solutions in drug development and manufacturing.
- The company has also significantly increased its R&D expenditure by ~40% to reinvest into next-gen materials, pharmaceuticals, and green tech- all high-growth, high-value sectors